Esperion Therapeutics Inc.
ESPR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$661.15M
Close$
$11.14
250.2% upside
Current Fair Value
250.2% upsideUndervalued by 250.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $661.15 Million |
|---|---|
| Enterprise Value | $801.15 Million |
| Annual dividend | $3.16 |
| Earnings per Share | $-0.11 |
| Beta | 1.06 |
| Outstanding Shares | 251,353,086 |
Return
| Return on Equity | -0.17% |
|---|---|
| Return on Assets | 0.11% |
| Return on Invested Capital | 47.14% |
Valuation & Multiples
| P/E Ratio | -131.4 |
|---|---|
| PEG | 348.38 |
| Price to Sales | 3.18 |
| Price to Book Ratio | -1.59 |
| Enterprise Value to Revenue | 1.92 |
| Enterprise Value to EBIT | 10.48 |
| Enterprise Value to Net Income | 1567 |
| Total Debt to Enterprise | 0.37 |
| Debt to Equity | -0.96 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.02
Consensus analyst estimateRevenue Estimate
$92.48 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 1.27, the ratio is above 1, so institutions hold more puts than calls. That is a more cautious stance.
| Put/Call Ratio | 1.2686▲ 100.93% |
|---|---|
| Total Calls | 826,900▼ 74.85% |
| Total Puts | 1,049,000▲ 23.05% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 81.93%▲ 12.37% |
|---|---|
| Total Invested | $649.17M▲ 35.45% |
| Investors Holding | 207▼ 13.00% |
About Esperion Therapeutics Inc.
CEO: Timothy Mayleben
